Press Releases Takeda Pharmaceutical Company Limited

Equities

4502

JP3463000004

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 01:30:00 2025-12-05 EST			5-day change	1st Jan Change
4,410.00 ^JPY	-1.41%		-1.61%	+5.48%

01:54am	Nikkei Falls Amid Caution Ahead of U.S. Inflation Data, Bond Yields Surge	MT
09:18pm	Innovent Biologics Closes Takeda Partnership, Issues New Shares	MT

Press Releases

Takeda Pharmaceutical : Announces Closing of Strategic Partnership with Innovent Biologics for Next-Generation Investigational Oncology Medicines	06:35pm	PU
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy	11-07	BU
New Phase 3 Data Show Takeda’s Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization	11-03	BU
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment. On Track for Multiple Regulatory Filings This Fiscal Year	10-30	BU
Takeda Pharmaceutical : Earnings Report（Kessan Tanshin）Earnings Report（Kessan Tanshin）Download Earnings Report（Kessan Tanshin） (qr2025 q2 er en)	10-30	PU
Takeda Pharmaceutical : PresentationPresentationDownload Presentation (qr2025 q2 p01 en)	10-30	PU
Takeda Pharmaceutical : Quarterly Financial ReportQuarterly Financial ReportDownload Quarterly Financial Report (qr2025 q2 qfr en)	10-30	PU
Takeda Pharmaceutical : Clinical Trials Summary (Clinical Trial Summary October 2025)	10-30	PU
Takeda Pharmaceutical : Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)	10-30	PU
Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2025 (IFRS)	10-30	EQ
HyHub™ and HyHub™ Duo Devices Now Available in the U.S. to Simplify HYQVIA® Infusion Preparation	10-27	BU
Takeda Enters Global Strategic Partnership with Innovent Biologics to Bolster Oncology Pipeline with Next-Generation Investigational Medicines for Treatment of Solid Tumors	10-21	BU
Takeda Pharmaceutical : to Hold Earnings Call for Fiscal Year 2025 2nd Quarter on October 30	10-16	PU
Takeda Pharmaceutical : Provides Update on Cell Therapy Research	10-01	PU
Takeda Pharmaceutical : Update on Construction of New Plasma-Derived Therapies Manufacturing Facility in Juso, Osaka	09-29	PU
Takeda Pharmaceutical : Information About General Reserve and Other Voluntary Reserves	09-24	PU
20,000 + Takeda Employees Voted to Select Four New Global Corporate Social Responsibility Collaborations to Advance Climate-Resilient Health Systems in 94 Countries	09-23	BU
Takeda and VELA to Ship Medicines Across the Atlantic Using First-of-its-Kind Wind-Powered Trimaran	09-16	BU
Takeda Appoints Rhonda Pacheco President of the U.S. Business Unit	09-11	BU
Takeda Presents Orexin Data from Landmark Oveporexton (TAK-861) Phase 3 Program in Narcolepsy Type 1 at World Sleep 2025	09-08	BU
U.S. FDA Approves Expanded Indication for VONVENDI® [von Willebrand factor (Recombinant)] for Adults and Children with Von Willebrand Disease	09-05	BU
Takeda's FRUZAQLA™ (fruquintinib) publicly reimbursed in Quebec for the treatment of metastatic colorectal cancer (mCRC)	08-28	AQ
Takeda Pharmaceutical : Statement on Inadvertent Abstract Disclosure for Opevorexton (TAK-861) by World Sleep Congress	07-31	PU
Takeda Announces First-Quarter FY2025 Results With Significant Late-Stage Pipeline Progression	07-30	BU
Takeda Pharmaceutical : Earnings Report（Kessan Tanshin）Earnings Report（Kessan Tanshin）Download Earnings Report（Kessan Tanshin） (qr2025 q1 er en)	07-30	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Takeda CEO Weber on Drug Pipeline, Geopolitical Risks

January 13, 2025 at 03:31 pm